Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
批准号:
7494784
负责人:
MARGARET A KELLER
金额:
$17.52万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2010-08-31
关键词:
AdolescentAdultAffectAgeAlgorithmsAmino AcidsAminobutyric AcidAminobutyric AcidsAnti-Retroviral AgentsAntioxidantsApplications GrantsAreaAttentionBasal GangliaBrainBrain regionCD4 Lymphocyte CountCD4 Positive T LymphocytesCerebrumChildCholineChronicChronic DiseaseClinicalCognitiveCreatineCrowdingCysteineDataDegenerative DisorderDementiaDetectionDevelopmentDimensionsDrug Metabolic DetoxicationEarly treatmentElevationEncephalitisEvaluationFutureGenderGliosisGlutamatesGlutamineGlutathioneGlycineGoalsGuidelinesHIVHIV InfectionsHealthHighly Active Antiretroviral TherapyImpaired cognitionIndividualInflammationInositolInvestigationLeftLongitudinal StudiesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMeasuresMembraneMetabolicMothersMotorMotor ActivityN-acetylaspartateNervous System TraumaNeuraxisNeurogliaNeurologicNeuronsNeuropsychological TestsNeurotransmittersNoiseOxidative StressParkinson DiseasePathologyPatientsPenetrationPerformancePharmaceutical PreparationsPhosphorylcholinePlasmaPublic HealthQuality of lifeReactionReportingResearch PersonnelScoreSignal TransductionSpectrum AnalysisSystemTechniquesTestingTimeViral Load resultYouthage relatedantiretroviral therapybasecognitive functioncohortcomputerizedcritical developmental periodexecutive functiongamma-Aminobutyric Acidimprovedinterestmotor impairmentmyelinationneurocognitive testperformance testsphosphoethanolaminetooltransmission processtwo-dimensional
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): HIV in adults and children has become a chronic illness and there is a critical need to develop noninvasive, reliable techniques to detect sub clinical involvement of the brain by HIV. Magnetic resonance spectroscopy (MRS) permits the study of HIV effects on cerebral metabolites, markers of neuronal and glial cell health. Most previous investigations have used 1.5 Tesla (T) scanners and one-dimensional MRS (1D-MRS) techniques. The primary goal of this study is to use an improved technique, a two-dimensional MRS technique (2D-MRS) on a 3 T scanner, to detect abnormal cerebral metabolites in HIV-infected patients, and to correlate abnormal cerebral metabolites with performance on neurocognitive tests, in order to better assess brain development and function in these individuals. A 3T scanner is expected to offer improved signal to noise ratios (SNR) and lower coefficients of variance compared to 1.5 T. The use of 2D-MRS allows the detection of many additional metabolites compared to traditional 1D-MRS by converting a crowded, overlapping 1D-MRS spectrum to a better resolved 2D spectrum through the addition of a spectral dimension. Of particular interest are GABA, an inhibitory neurotransmitter and myo-inositol (mI), a glial cell marker for which elevation suggests ongoing inflammation. Metabolite ratios to reference metabolites and metabolite concentrations will be determined. The 3 Tesla scanner combined with 2D-MRS also provides the ability to study glutathione (GSH), an important cellular antioxidant protector molecule that could assess central nervous system damage by the HIV virus. The specific aims of this study are to compare GABA, mI, choline groups, GSH and other metabolites in the right frontal brain region and right basal ganglia of 30 HIV-infected patients and 30 control subjects. Both of these areas of the brain have been documented to be involved in the central nervous system pathology of HIV. The hypotheses are that GABA and mI will be increased in HIV-infected patients while GSH will be decreased and that the changes in concentrations of these metabolites will correlate with poorer performance on neurocognitive tests of executive functioning, fine motor activity, and attention. In addition to the better assessment of brain development and function, reliable identification of perinatally HIV-infected youths with abnormal cerebral metabolites and sub clinical brain involvement by 2D-MRS (3T) may also direct earlier therapy than the current CD4 count criteria would indicate or changing existing HAART therapy to antiretroviral medications with improved CNS penetration. This study could potentially improve the quality of life of HIV-infected youths and preserve the health of the central nervous system. PUBLIC HEALTH RELEVANCE This study plans to identify metabolite markers of HIV involvement of the brain using noninvasive magnetic resonance spectroscopy in perinatally HIV-infected youths. Cerebral metabolite levels will be correlated with performance on neuropsychological tests and will identify involvement of the brain before clinical detection. Such results could dictate earlier therapy in children and youths with high CD4 cells or a change in antiretroviral medication to better treat HIV infection of the brain and improve the quality of life and neurological health of the millions of children worldwide infected with HIV from the mother.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
-
批准号:8174501
-
项目类别:
-
资助金额:$0.86万
-
财政年份:2009
-
负责人:MARGARET A KELLER
-
依托单位:
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
-
批准号:7952269
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2008
-
负责人:MARGARET A KELLER
-
依托单位:
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY
-
批准号:7606170
-
项目类别:
-
资助金额:$0.74万
-
财政年份:2007
-
负责人:MARGARET A KELLER
-
依托单位:
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN VERTICALLY HIV-INFEC
-
批准号:7376075
-
项目类别:
-
资助金额:$1.03万
-
财政年份:2005
-
负责人:MARGARET A KELLER
-
依托单位:
MONTHER-INFANT RAPID INTERVENTION AT DELIVERY (MIRIAD)
-
批准号:7206392
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2004
-
负责人:MARGARET A KELLER
-
依托单位:
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN
-
批准号:7206388
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2004
-
负责人:MARGARET A KELLER
-
依托单位:
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS. PRO
-
批准号:7042126
-
项目类别:
-
资助金额:$0.39万
-
财政年份:2003
-
负责人:MARGARET A KELLER
-
依托单位:
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN
-
批准号:7042137
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2003
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF
-
批准号:6416298
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V
-
批准号:6416325
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG353 ORAL NELFINAVIR CO ADMINISTERED W/ ZIDOVUDINE & LAMIVUDINE IN
-
批准号:6416327
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM
-
批准号:6416297
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG250 NEVIRAPINE IN HIV 1 INFECTED PREGNANT WOMEN&NEONATES BORN TO
-
批准号:6416324
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F
-
批准号:6416326
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
PHASE III RANDOMIZED DOUBLE BLIND CONTROLLED STUDY OF HYPERIMMUNE ANTI HIVG
-
批准号:6416381
-
项目类别:
-
资助金额:$23.8万
-
财政年份:2000
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM
-
批准号:6306584
-
项目类别:
-
资助金额:$0.1万
-
财政年份:1999
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F
-
批准号:6306613
-
项目类别:
-
资助金额:$0.1万
-
财政年份:1999
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF
-
批准号:6306585
-
项目类别:
-
资助金额:$0.1万
-
财政年份:1999
-
负责人:MARGARET A KELLER
-
依托单位:
PHASE III CLINICAL STUDY OF HYPERIMMUNE ANTI HIVIG PREVENTION OF AIDS IN INFANTS
-
批准号:6117108
-
项目类别:
-
资助金额:$3.89万
-
财政年份:1998
-
负责人:MARGARET A KELLER
-
依托单位:
ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V
-
批准号:6264907
-
项目类别:
-
资助金额:$0.1万
-
财政年份:1998
-
负责人:MARGARET A KELLER
-
依托单位:
海外基金